## Abstract The prognosis of diffuse large Bβcell lymphoma (DLBCL) has improved markedly in recent years of rituximab era. The prognosis of __de novo__ CD5βpositive DLBCL is reported to be poor, but the effect of rituximab on this type of lymphoma remains unclear. To investigate the effect of ritux
β¦ LIBER β¦
Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma
β Scribed by Nakamura, N; Kuze, T; Hashimoto, Y; Hara, Y; Hoshi, S; Sasaki, Y; Shirakawa, A; Sato, M; Abe, M
- Book ID
- 110054802
- Publisher
- Nature Publishing Group
- Year
- 2001
- Tongue
- English
- Weight
- 105 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0887-6924
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The therapeutic effect of rituximab on C
β
Rie Hyo; Naoto Tomita; Kengo Takeuchi; Tomohiro Aoshima; Atsuko Fujita; Hideyuki
π
Article
π
2009
π
John Wiley and Sons
π
English
β 111 KB
Aggressive CD5-positive B-cell lymphoma
β
Takashi Sonoki; Sonoko Ishihara; Shima Uneda; Nobuyoshi Hanaoka; Miwa Kurimoto;
π
Article
π
2008
π
Carden Jennings Publishing
π
English
β 366 KB
Somatic Hypermutations in the VHSegment
β
Kume, Masaaki ;Suzuki, Ritsuro ;Yatabe, Yasushi ;Kagami, Yoshitoyo ;Miura, Ikuo
π
Article
π
1997
π
Wiley (Blackwell Publishing)
π
English
β 412 KB
Primary diffuse large B cell lymphoma of
β
Driessen, A; Tierens, A; Ectors, N; Stul, M; Pittaluga, S; Geboes, K; Delabie, J
π
Article
π
1999
π
Nature Publishing Group
π
English
β 202 KB
Expression profiling analysis of the CD5
β
Miyuki Suguro; Hiroyuki Tagawa; Yoshitoyo Kagami; Masataka Okamoto; Koichi Ohshi
π
Article
π
2006
π
John Wiley and Sons
π
English
β 311 KB
Biased utilization of immunoglobulin var
β
Mohammad Moazzeni; Ghasem Mosayyebi; Freda K. Stevenson; Sandra Abbot; Rizgar A.
π
Article
π
1994
π
John Wiley and Sons
π
French
β 846 KB
Twenty-six established Burkitt's lymphoma (BL) cell lines from endemic or sporadic groups of patients were examined for the expression of cross-reactive idiotypes (CRI) associated with VHI, V,III. VHIV, VHVI, VKllla and VKlllb heavy-and light-chain gene products, using a panel of anti-CRI and anti-s